Loading
Myomo, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Getz Heather C, was filed 17 Mar 2026.
Myomo, Inc.: what insiders have been doing
This page follows insider dealings at Myomo, Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. 14 insiders have disclosed 52 filings since 22 October 2025.
Purchases and sales both appear in the filings: 7 purchases (3 insiders, €108k) and 6 sales (3 insiders, €174k). Taken together, the sales exceed the purchases by €65k. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The largest single trade was a sale of €69k by Mitchell Micah, published on 15 May 2026, equal to 0.12% of the market capitalisation. Among those who bought: 3 senior executives.
The data flag 4 purchases as part of a group of insiders buying within 30 days of each other. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. The clock since the last published purchase (17 March 2026) now reads 220 days. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4.
With 52 filings in twelve months, the company is more active than the median of 41 filings across the 2,023 companies we follow on the same exchange. The full history, which starts in 2017, counts 39 purchases against 22 sales. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 40.9 m USD and net income of -15.6 m USD.
Elsewhere in the same sector, our signals recently picked up insider purchases at Xenon Pharmaceuticals Inc. and Vivos Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
314
Thresholds
n/a
Buy Volume
€1M
39 ops. · all time
Sell Volume
€740,213
22 ops. · all time
Who traded when
BuySaleKirk Thomas F9 buys
Harry Kovelman5 sales
Crowley Thomas Aloysius Jr.2 buys
Getz Heather C2 buys
Micah Mitchell2 sales
Paul R. Gudonis2 buys
+1 other insider
Since the insiders bought
- +111.0%Entry US$0.73 · Close at T+90 US$1.53
- +87.2%Entry US$0.72 · Close at T+90 US$1.35
- -12.9%Entry US$0.84 · Close at T+90 US$0.73
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 24,366 of 26,246 companies
18.5
score / 100
Value7
Quality30
FCF yld-36%
Earn yld-31%
EV/EBITDA·
ROE-124%
Gross mgn66%
Net mgn-38%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$1.26
Analyst consensus
5 analysts1.20/5
US$1.70Target US$4.64(+268%)US$10.50
Income statement
RevenueUS$40.9M
Gross profitUS$26.9M66% margin
EBITDA-US$12.6M-31% margin
Net income-US$15.6M-33.5% margin
Valuation
PER (forward)-5.7x
P/Book8.6x
Beta1.58
Balance sheet & cash
Market capUS$49.9M
Total debtUS$19.4M
Free Cash Flow-US$17.8M
Debt / Equity344%
Profitability & ownership
ROE-123.8%
ROA-19.8%
% insiders10.1%
% institutions37.9%
Last declaration on 15 October 2026
Declarations314 total
32,500 shares0Common StockSEC:0001193125-26-422937:0
51,250 shares0Common StockSEC:0001193125-26-422923:0
71,250 shares0Common StockSEC:0001193125-26-422913:0
15,844 shares@ US$1.27090.038% mcap4.2% of flowCommon StockSEC:0001193125-26-422930:0
3,133 shares@ US$1.370.0084% mcap43.6% of flowCommon StockSEC144:0001193125-26-419828
6,272 shares0Common StockSEC:0001193125-26-420694:0
8,363 shares0Common StockSEC:0001193125-26-420689:0
275,000 shares0Common StockSEC:0001193125-26-419757:0
3,133 shares@ US$1.370.0076% mcap1.3% of flowCommon StockSEC:0001193125-26-420694:1
15,488 shares@ US$1.27090.040% mcap4.1% of flowCommon StockSEC:0001193125-26-390646:0
15,844 shares@ US$1.27090.041% mcap40.0% of flowCommonSEC144:0001950047-26-009368
15,000 shares@ US$1.410.033% mcap15.2% of flowCommon StockSEC:0001193125-26-383718:0
17,500 shares@ US$1.73310.046% mcap6.6% of flowCommon StockSEC:0001193125-26-361870:0
17,250 shares@ US$1.73310.046% mcap6.5% of flowCommon StockSEC:0001193125-26-361391:0
17,500 shares@ US$1.73310.046% mcap60.0% of flowCommonSEC144:0001950047-26-008448
146,909 shares0Common StockSEC:0001193125-26-343465:0
68,644 shares0Common StockSEC:0001193125-26-343460:0
55,149 shares0Common StockSEC:0001193125-26-343483:0
58,409 shares0Common StockSEC:0001193125-26-343470:0
25,310 shares@ US$1.420.056% mcap10.4% of flowCommon StockSEC:0001193125-26-343460:1
22,457 shares@ US$1.420.049% mcap7.0% of flowCommon StockSEC:0001193125-26-343483:1
21,559 shares@ US$1.420.047% mcap7.7% of flowCommon StockSEC:0001193125-26-343470:1
5,166 shares@ US$1.090.0088% mcap100.0% of flowCommon StockSEC144:0001193125-26-302069
10,454 shares0Common StockSEC:0001193125-26-302072:0
7,840 shares0Common StockSEC:0001193125-26-302089:0
25 of 314 declarations
About Myomo, Inc.
Myomo, Inc. is a U.S.-based medical technology and wearable medical robotics company listed on NYSE American (within the broader NYSE/NASDAQ U.S. listed universe for international investors). The company is headquartered in Burlington, Massachusetts, United States, and markets the MyoPro® product line, a lightweight, non-invasive powered orthosis for the arm and hand. MyoPro is designed for individuals with upper-limb paralysis or weakness caused by stroke, spinal cord injury, nerve injury such as brachial plexus injury, and other neuromuscular disorders. Myomo says the product is built on patented technology developed at MIT and Harvard Medical School and uses non-invasive sensors to detect a patient’s own neurological signals and translate them into assisted movement. ([myomo.com](https://myomo.com/about-myomo/?utm_source=openai))
Founded in the mid-2000s, Myomo has evolved from an R&D-driven medtech business into a commercial-stage company focused on neuromuscular rehabilitation and upper-extremity functional restoration. Its business model centers on clinical referrals, orthotics and prosthetics (O&P) providers, rehabilitation centers, and hospital networks, rather than direct-to-consumer sales. The company states that MyoPro is fitted and delivered through a nationwide network of O&P practices across the U.S., supported by sales and clinical professionals spread across the country. Myomo also maintains an international sales channel, which it highlighted as a source of record fourth-quarter revenue in 2025. ([myomo.com](https://myomo.com/about-myomo/?utm_source=openai))
Read moreShow less
From a competitive standpoint, Myomo occupies a niche position in assistive medical robotics. The category is specialized, clinically intensive, and relatively difficult to penetrate because it requires regulatory clearance, clinician training, reimbursement execution, and evidence generation. Myomo’s differentiation lies in being one of the few companies focused specifically on powered upper-limb orthoses for neurologically impaired patients. The company emphasizes clinical referrals from well-known institutions such as Mayo Clinic, Cleveland Clinic, Massachusetts General Hospital, Kennedy Krieger Institute, Loma Linda Medical Center, and multiple Veterans Health Administration hospitals. It also says more than 600 patients have used MyoPro, underscoring a meaningful installed base in a still-emerging market. ([myomo.com](https://myomo.com/about-myomo/?utm_source=openai))
Recent operating updates suggest improving commercial momentum. Myomo reported first-quarter 2025 revenue of $9.8 million and a record addition to its patient pipeline; second-quarter 2025 revenue of $9.7 million with 816 patients added to the pipeline; third-quarter 2025 revenue of $10.1 million with 229 authorizations and orders; and fourth-quarter 2025 revenue of $11.4 million, bringing full-year 2025 revenue to $40.9 million. The company also introduced 2026 revenue guidance of $43 million to $46 million and noted that 42% of fourth-quarter revenue came from recurring patient sources. Management has increasingly stressed growth in the O&P channel, broader referral pathways, and a shift toward lower-cost recurring patient acquisition. ([myomo.com](https://myomo.com/myomo-reports-first-quarter-2025-financial-and-operating-results/?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
